MX9803805A - Uso de resonancia magnetica nuclear para diseñar ligandos dirigidos a biomoleculas. - Google Patents

Uso de resonancia magnetica nuclear para diseñar ligandos dirigidos a biomoleculas.

Info

Publication number
MX9803805A
MX9803805A MX9803805A MX9803805A MX9803805A MX 9803805 A MX9803805 A MX 9803805A MX 9803805 A MX9803805 A MX 9803805A MX 9803805 A MX9803805 A MX 9803805A MX 9803805 A MX9803805 A MX 9803805A
Authority
MX
Mexico
Prior art keywords
target molecule
ligands
magnetic resonance
nuclear magnetic
target biomolecules
Prior art date
Application number
MX9803805A
Other languages
English (en)
Inventor
Stephen W Fesik
Philip J Hajduk
Edward T Olejniczak
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27415774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9803805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/558,633 external-priority patent/US5891643A/en
Priority claimed from US08/744,701 external-priority patent/US5989827A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX9803805A publication Critical patent/MX9803805A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4633—Sequences for multi-dimensional NMR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona un proceso para diseñar compuestos que se fijen a una molécula objetivo específica. El proceso incluye los pasos de a) identificar un primer ligando para la molécula objetivo, usando espectroscopía de correlacion de resonancia magnética nuclear de 15N/1H bidimensional; b) identificar un segundo ligando para la molécula objetivo usando espectroscopía de correlacion de resonancia magnética nuclear de 15N/1H bidimensional; c) formar un complejo ternario mediante la fijacion del primero y segundo ligandos a la molécula objetivo; d) determinar la estructura tridimensional del complejo y, de esta manera, la orientacion espacial del primero y segundo ligandos en la molécula objetivo; y e) enlazar el primero y segundo ligados para formar el fármaco, en donde se mantenga la orientacion espacial del paso d).
MX9803805A 1995-11-14 1998-05-13 Uso de resonancia magnetica nuclear para diseñar ligandos dirigidos a biomoleculas. MX9803805A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/558,633 US5891643A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to design ligands to target biomolecules
US67890396A 1996-07-12 1996-07-12
US08/744,701 US5989827A (en) 1995-11-14 1996-10-31 Use of nuclear magnetic resonance to design ligands to target biomolecules

Publications (1)

Publication Number Publication Date
MX9803805A true MX9803805A (es) 1998-09-30

Family

ID=27415774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803805A MX9803805A (es) 1995-11-14 1998-05-13 Uso de resonancia magnetica nuclear para diseñar ligandos dirigidos a biomoleculas.

Country Status (12)

Country Link
EP (1) EP0870197B2 (es)
JP (1) JP3300366B2 (es)
AT (1) ATE201768T1 (es)
AU (1) AU711092B2 (es)
DE (1) DE69613146T3 (es)
DK (1) DK0870197T4 (es)
ES (1) ES2159056T5 (es)
GR (1) GR3036454T3 (es)
IL (1) IL123572A (es)
MX (1) MX9803805A (es)
PT (1) PT870197E (es)
WO (1) WO1997018469A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
EP1104488B1 (en) * 1998-07-21 2006-10-25 Rutgers, The State University Linking gene sequence to gene function by three dimensional (3d) protein structure determination
US6333149B1 (en) 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
WO2001062688A2 (en) * 2000-02-25 2001-08-30 Wyeth Methods of structure-based drug design using ms/nmr
EP1322942B1 (en) 2000-09-27 2014-03-26 Universiteit Leiden Method for applying nmr for ligand discovery or as a drug screening tool
US7653490B2 (en) 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
NO20025738D0 (no) * 2002-11-29 2002-11-29 Amersham Health As Metode
JP4192078B2 (ja) 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
JP4475237B2 (ja) * 2004-02-02 2010-06-09 三菱化学株式会社 Ｎｍｒシグナル帰属方法
EP2013624B1 (en) 2006-03-14 2011-08-03 Universität Basel Method for the identification of new leads for drug candidates
WO2019060917A2 (en) * 2017-09-25 2019-03-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPREADING MODULATORS
CN117912601A (zh) * 2024-01-26 2024-04-19 苏州腾迈医药科技有限公司 分子构象的展示方法及装置、介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010140A2 (en) * 1989-12-29 1991-07-11 University Technologies International Inc. Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5393669A (en) * 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US8558663B2 (en) † 2007-11-30 2013-10-15 Bank Of America Corporation Integration of facial recognition into cross channel authentication
DE102008042959A1 (de) † 2008-10-20 2010-04-22 Zf Friedrichshafen Ag Verfahren zur Steuerung eines Kraftfahrzeug-Antriebsstrangs
US8678903B1 (en) † 2012-09-13 2014-03-25 Chia-Yen Lin Mobile device having a virtual spin wheel and virtual spin wheel control method of the same

Also Published As

Publication number Publication date
AU7680496A (en) 1997-06-05
EP0870197A2 (en) 1998-10-14
DK0870197T3 (da) 2001-08-27
AU711092B2 (en) 1999-10-07
DK0870197T4 (da) 2007-02-26
ES2159056T3 (es) 2001-09-16
JP2002510384A (ja) 2002-04-02
ATE201768T1 (de) 2001-06-15
GR3036454T3 (en) 2001-11-30
JP3300366B2 (ja) 2002-07-08
WO1997018469A3 (en) 1997-08-07
IL123572A (en) 2004-06-01
DE69613146D1 (de) 2001-07-05
IL123572A0 (en) 1998-10-30
DE69613146T2 (de) 2003-01-16
EP0870197B1 (en) 2001-05-30
DE69613146T3 (de) 2007-06-14
ES2159056T5 (es) 2007-07-16
EP0870197B2 (en) 2006-11-08
PT870197E (pt) 2001-11-30
WO1997018469A2 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
GR3032361T3 (en) Use of nuclear magnetic resonance to identify ligands to target biomolecules
MX9803805A (es) Uso de resonancia magnetica nuclear para diseñar ligandos dirigidos a biomoleculas.
CA2653959A1 (en) Method for identifying ligands
CA2286795A1 (en) Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
Gao et al. Cyclic (Alkyl)(amino) carbene Ligands Enable Cu‐Catalyzed Markovnikov Protoboration and Protosilylation of Terminal Alkynes: A Versatile Portal to Functionalized Alkenes
Ernsting et al. 103Rh NMR spectroscopy and its application to rhodium chemistry
Brechbiel et al. Preparation of the Novel Chelating Agent N-(2-Aminoethyl)-trans-1, 2-diaminocyclohexane-N, N ‘, N ‘‘-pentaacetic Acid (H5CyDTPA), a Preorganized Analogue of Diethylenetriaminepentaacetic Acid (H5DTPA), and the Structures of BiIII (CyDTPA) 2-and BiIII (H2DTPA) Complexes
Chang et al. An unusually stable manganese (II) manganese (III) complex with novel EPR spectra: synthesis, structure, magnetism, and EPR analysis
Esteruelas et al. Synthesis of Hydrido− Vinylidene and Hydrido− Carbyne Osmium Complexes Containing Pyrazole: New Examples of N− H⊙⊙⊙ Y (Y= N, F, Cl) Hydrogen Bonds
ATE216777T1 (de) Affinitäts-selektion von liganden mittels massenspektroskopie
Reveco et al. Study of a cyclometalated complex of ruthenium by 400-MHz two-dimensional proton NMR
Peterson et al. Iron-Catalyzed C (sp2)–C (sp3) Suzuki–Miyaura Cross-Coupling Using an Alkoxide Base
Pregosin et al. 2-D NMR Spectroscopy of chiral phosphine complexes. Applications to problems related to enantioselective homogeneous catalysis
Auth et al. Modular ion mobility calibrants for organometallic anions based on tetraorganylborate salts
Abram et al. trans-Dichlorooxo (2-propoxido) bis (triphenylphosphine) rhenium (V)
Juarez-Garcia et al. Combined Moessbauer and EPR studies of the S= 3 state of an exchange-coupled iron (III)-copper (II) complex: test for quantitative EPR analysis of integer spin systems
Nakazawa et al. Migration of the phosphorus ligand from iron to the cyclopentadienyl ring in complexes of the type (. eta. 5-C5H5)(CO) LFe {P (O) YZ}
Cabeza et al. Dinuclear p-cymeneosmium hydride complexes; the measurement of 187 Os chemical shifts using 1 H-{187 Os} two-dimensional nmr spectroscopy
Estiú et al. Calculations on the Electronic Structure and UV− Visible Spectrum of Oxyhemocyanin
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
Arlen et al. Synthesis and reactivity of cyclonickelated compounds. Crystal and molecular structure of [Ni (CCF 3 [double bond, length as m-dash] CCF 3 CH 2 C 6 H 4 NMe 2)(PEt 3)(µ-Cl)] 2
Crane Chemistry of the Tp'W (O) fragment
Heaton NMR Studies of metal complexes and clusters with carbonyls and phosphines
Wingren Surface properties of antibodies and their complexes with antigens studied by LLPC.
Pinkas et al. Origin of different coordination polyhedra for Cu [CF {sub 3} C (O) CHC (O) CF {sub 3}]{sub 2} L (L= H {sub 2} O, NH {sub 3})